| Dr Jeffry Carle Ruff Jr, DO | |
|
1222 Trotwood Ave, Ste. 101, Columbia, TN 38401-6436 | |
| (931) 490-7348 | |
| (931) 490-7349 |
| Full Name | Dr Jeffry Carle Ruff Jr |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 14 Years |
| Location | 1222 Trotwood Ave, Columbia, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265753339 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maury Regional Hospital | Columbia, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maury Regional Medical Group, Inc | 7911810742 | 97 |
| Cep America - Neurology Pc | 3971871500 | 56 |
News Archive
For the first time, researchers studying patients with abnormal moles have identified proteins that could help predict whether such moles will progress into melanoma, the deadliest form of skin cancer.
There may be some scenarios in which patient decision aids should be designed to "nudge" patients toward a particular treatment option, according to a report by US researchers.
Applied Spine Technologies, Inc. www.appliedspine.com, a medical device company focused on motion preservation of the lumbar spine, has been awarded a new patent titled "Spinal Stabilization Device with Weld Cap".
Almost two-thirds of non-diabetic patients with Parkinson's disease may be insulin resistant, despite having normal blood sugar, report scientists in the Journal of Parkinson's Disease.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107") for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics.
› Verified 2 days ago
| Entity Name | Maury Regional Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205886264 PECOS PAC ID: 7911810742 Enrollment ID: O20040227000252 |
News Archive
For the first time, researchers studying patients with abnormal moles have identified proteins that could help predict whether such moles will progress into melanoma, the deadliest form of skin cancer.
There may be some scenarios in which patient decision aids should be designed to "nudge" patients toward a particular treatment option, according to a report by US researchers.
Applied Spine Technologies, Inc. www.appliedspine.com, a medical device company focused on motion preservation of the lumbar spine, has been awarded a new patent titled "Spinal Stabilization Device with Weld Cap".
Almost two-thirds of non-diabetic patients with Parkinson's disease may be insulin resistant, despite having normal blood sugar, report scientists in the Journal of Parkinson's Disease.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107") for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics.
› Verified 2 days ago
| Entity Name | Cep America - Neurology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639788250 PECOS PAC ID: 3971871500 Enrollment ID: O20221021001901 |
News Archive
For the first time, researchers studying patients with abnormal moles have identified proteins that could help predict whether such moles will progress into melanoma, the deadliest form of skin cancer.
There may be some scenarios in which patient decision aids should be designed to "nudge" patients toward a particular treatment option, according to a report by US researchers.
Applied Spine Technologies, Inc. www.appliedspine.com, a medical device company focused on motion preservation of the lumbar spine, has been awarded a new patent titled "Spinal Stabilization Device with Weld Cap".
Almost two-thirds of non-diabetic patients with Parkinson's disease may be insulin resistant, despite having normal blood sugar, report scientists in the Journal of Parkinson's Disease.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107") for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffry Carle Ruff Jr, DO 1222 Trotwood Ave, Ste. 101, Columbia, TN 38401-6436 Ph: (931) 490-7348 | Dr Jeffry Carle Ruff Jr, DO 1222 Trotwood Ave, Ste. 101, Columbia, TN 38401-6436 Ph: (931) 490-7348 |
News Archive
For the first time, researchers studying patients with abnormal moles have identified proteins that could help predict whether such moles will progress into melanoma, the deadliest form of skin cancer.
There may be some scenarios in which patient decision aids should be designed to "nudge" patients toward a particular treatment option, according to a report by US researchers.
Applied Spine Technologies, Inc. www.appliedspine.com, a medical device company focused on motion preservation of the lumbar spine, has been awarded a new patent titled "Spinal Stabilization Device with Weld Cap".
Almost two-thirds of non-diabetic patients with Parkinson's disease may be insulin resistant, despite having normal blood sugar, report scientists in the Journal of Parkinson's Disease.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107") for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics.
› Verified 2 days ago
Ralph I Barr, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 801 School St, Columbia, TN 38401 Phone: 931-490-1400 Fax: 931-490-1462 | |
Anthony Chuka Ekwo, M.D. MPH Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: Ruth Clinic, 1300 Hatcher Lane, Columbia, TN 38401 Phone: 931-548-3177 | |
Louise Y Ledbetter, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 927 N. James Campbell Blvd., Suite 105, Columbia, TN 38401 Phone: 931-388-5114 Fax: 931-388-5631 | |
Dr. Sarath Gangavarapu, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1001 N James Campbell Blvd, Columbia, TN 38401 Phone: 931-777-6180 | |
Dr. Elizabeth Ann Null, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1222 Trotwood Ave, Suite 101, Columbia, TN 38401 Phone: 931-490-7348 Fax: 931-490-7349 | |
Glenn R Yank, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 854 W James Campbell Blvd, Suite 201, Columbia, TN 38401 Phone: 931-490-0999 Fax: 931-490-0555 |